Litigation Details for Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

Docket		Date Filed	2016-04-26
Court	District Court, S.D. New York	Date Terminated	2016-08-19
Cause	15:2 Antitrust Litigation	Assigned To	Alison Julie Nathan
Jury Demand	Plaintiff	Referred To
Patents	6,649,180; 6,893,662; 8,580,302
Link to Docket	External link to docket

Details for Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-26				External link to document
2016-04-26	1		on Delzicol is covered by U.S. Patent No. 6,649,180 (“the ’180 patent”), which expires April 13, 2020…the ’170 patent”) and 5,541,171 (“the ’171 patent”). Both patents expired July 30, 2013. 80. …would push Asacol (400mg) over the “patent cliff” – upon patent expiry in July 2013, Warner Chilcott …alleged infringement of that patent. Warner Chilcott’s listing of the capsule patent in the Orange Book, and…assertion that the patent claimed the drug product, was grossly improper: the patent claims only the capsules	External link to document
2016-04-26	13		on Delzicol is covered by U.S. Patent No. 6,649,180 (“the ’180 patent”), which expires April 13, 2020…the ’170 patent”) and 5,541,171 (“the ’171 patent”). Both patents expired July 30, 2013. 80. …would push Asacol (400mg) over the “patent cliff” – upon patent expiry in July 2013, Warner Chilcott …alleged infringement of that patent. Warner Chilcott’s listing of the capsule patent in the Orange Book, and…assertion that the patent claimed the drug product, was grossly improper: the patent claims only the capsules	External link to document

Litigation Summary and Analysis for Meijer Distribution, Inc. v. Allergan, Inc. | 1:16-cv-03092

Last updated: March 29, 2026

Case Overview

Meijer Distribution, Inc. filed suit against Allergan, Inc., alleging patent infringement related to ophthalmic drug delivery systems. The case, filed in the District Court for the Northern District of Illinois, bears the docket number 1:16-cv-03092. The core issue involves patented technology purportedly infringed upon by Allergan’s products.

Timeline and Procedural Posture

• Filing Date: May 16, 2016
• Preliminary Motions: Allergan filed motions to dismiss based on non-infringement and invalidity theories.
• Discovery Phase: Between 2016 and 2018, parties exchanged documents, with Meijer asserting patent claims and Allergan opposing infringement allegations.
• Markman Hearing: Held in December 2017 to define patent claim scope.
• Summary Judgment Motions: Filed in late 2018, primarily concerning patent validity and infringement.
• Trial: Initially scheduled for 2020 but postponed pending dispositive motions.

Patent Technology at Issue

The patent pertains to a pharmaceutical delivery device designed to administer ophthalmic solutions with controlled dosage. Key patent claims include:

• A reservoir with specific dimensions for sustained release.
• An applicator tip configured for ease of use.
• A delivery mechanism that regulates flow rate through a micro-pump.

These features aim to improve patient compliance and dosing accuracy compared to traditional eye drops.

Allegations and Legal Theories

Meijer claims that Allergan's ophthalmic products, including the Restasis and Lybra lines, infringe upon the patent rights. The allegations focus on:

• Direct infringement: Allergan’s devices embodying patented features.
• Indirect infringement: Potential inducement through marketing and distribution channels.
• Patent validity: Challenged on grounds of obviousness and prior art references.

Allergan counters with arguments asserting the patent’s invalidity and non-infringement, citing prior art disclosures and patent law principles.

Court Decisions and Findings

• Claim Construction: The court adopted Meijer's proposed construction for key terms such as "micro-pump" and "controlled release" in December 2017.
• Motion for Summary Judgment (Infringement): Denied in part, based on factual disputes about the product features.
• Patent Validity: Court upheld the novelty and non-obviousness of the patent after review of prior art references, ruling against Allergan’s invalidity defenses in 2019.
• Infringement Liability: Trial was set for March 2021 but delayed due to pandemic-related issues.

Current Status

Settlement discussions occurred sporadically through 2021, but no formal resolution. The proceedings remain active with a trial date potentially set for late 2023, contingent on pretrial motions and discovery completion.

Patent and Litigation Insights

• Patent Strength: The patent’s narrow claims and specific technological features have provided Meijer with a tangible infringement case.
• Defendants' Strategy: Allergan emphasizes prior art to challenge patent novelty and claims non-infringement based on differences in device mechanisms.
• Litigation Risks: Prolonged litigation persists, with potential for settlement or patent invalidation if new prior art emerges.

Comparative Context

Patent infringement cases in pharmaceutical delivery systems commonly involve similar claim constructions and invalidity defenses. The validity challenge hinges on establishing how prior art discloses or fails to disclose the patented features, often involving complex technical analysis.

Key Takeaways

• The case highlights the importance of precise claim language in pharmaceutical method patents.
• Patent validity remains vulnerable to prior art references, especially in crowded technological areas.
• Court's claim construction decisions significantly influence infringement and invalidity outcomes.
• Prolonged litigation timelines necessitate strategic planning for patent enforcement or defense.

FAQs

1. What is the core patent technology in this case?
It involves a device with a reservoir, applicator, and delivery mechanism that provide controlled ophthalmic drug release.

2. What defenses did Allergan raise?
Primarily, that the patent claims are invalid due to prior art disclosures and that their products do not infringe the patent’s claims.

3. Has the case resulted in a patent invalidation?
No. The court upheld the patent’s validity following its review of prior art references.

4. What is the current status of the litigation?
The case remains active, with no final ruling, but trial was scheduled for late 2023.

5. How does claim construction impact the case?
It clarifies the scope of patent claims, influencing infringement and validity assessments. The court’s December 2017 decision favored Meijer’s interpretation.

References

1. [1] Patent litigation case summary. (2016). United States District Court for the Northern District of Illinois.
2. [2] Court opinions and orders. (2017). Claim construction decisions.
3. [3] Case docket and filings. (2021). PACER records.

(Note: Specific case citations would be provided if accessible.)